Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update


"The third quarter of 2007 was marked by a number of milestones for Exelixis," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "During the quarter, we clarified ownership of our lead compound, XL647, and began with GSK an accelerated review of XL880, which we believe to be the most advanced MET inhibitor in clinical development. We also presented encouraging phase 2 clinical data for XL647 and continued to make preparations to begin pivotal trials for the compound in the first half of next year. After the quarter closed, we presented encouraging clinical data on seven of our other pipeline compounds at the AACR-NCI-EORTC conference, as well as updated data for XL647. Throughout the quarter, we continued to effectively manage our finances and should finish the year with more than $270 million."

Financial Outlook

With respect to financial expectations for the full year 2007, we are reducing our revenue guidance to a range of $110.0 to $120.0 million from a range of $120.0 to $135.0 million due principally to a change in timing as it relates to a potential selection milestone under our collaboration with GSK. We are maintaining our operating expense guidance at $260.0 to $290.0 million and we are increasing our guidance for cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. and restricted cash and investments to a balance of greater than $270.0 million at the end of the year.

Conference Call and Webcast

Exelixis' management will discuss the company's financial results for the quarter ended September 30, 2007, on a conference call beginning at 2:00 p.m. PT/ 5:00 p.m. ET today, Monday, November 5, 2007. To listen to a webcast of the discussion, visit the Event Calendar page under Investors at

About Exelixis

Exelixis, Inc. is a develo

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
(Date:8/3/2015)... ... ... Nine field days to promote practices that improve soil health will take place ... , the field days will demonstrate how changing certain practices, such as adding cover ... Brent Bible has practiced no-till farming and planted cover crops on his farm in ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... 31 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... of,early lung cancer detection testing and other ... Strategies LLC, a government consulting,firm focused on ... appropriations and development of advanced technologies. ...
... TARRYTOWN, N.Y., Oct. 31 Emisphere,Technologies, Inc. ... will move its,corporate headquarters from Tarrytown, New ... retain its scientific staff and laboratory,facilities in ... that focuses on a unique and improved ...
... IDIX ) announced today that it will report,its ... Tuesday, November 6,2007 after the U.S. financial markets close. ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,2007. To ...
Cached Biology Technology:Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts 2Emisphere Technologies, Inc. Moves Into New Corporate Headquarters 2Emisphere Technologies, Inc. Moves Into New Corporate Headquarters 3
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... nature has long been suspected to increase positive ... pain associated with recovery from surgery. Now, research ... flowers for patients recovering from abdominal surgery. ... H. Mattson, researchers from the Department of Horticulture, ...
... expressions of emotion are hardwired into our genes, according ... of Personality and Social Psychology . The research suggests ... a product of cultural learning. The study is the ... blind individuals use the same facial expressions, producing the ...
... the University of Warwick has discovered the trigger that pulls ... of embryo development. Their discovery could also provide new insights ... are bound together at key parts of analogous cell processes. ... togetgher of too many of too few of a particular ...
Cached Biology News:Flowering plants speed post-surgery recovery 2Facial expressions of emotion are innate, not learned, says new study 2How chromosomes meet in the dark -- Switch that turns on X chromosome matchmaking 2How chromosomes meet in the dark -- Switch that turns on X chromosome matchmaking 3